The deal with Salud Interactiva will make Pathway's next-generation sequencing-based tests available in Mexico.
Researchers saw a small, but significant uptick in self-reported healthy eating and exercise frequency after 23andMe or Pathway Genomics DTC testing.
A new PGen study reports that nearly 6 percent of consumers made changes to their prescription medication based on pharmacogenomic testing.
Under the terms of the agreement, M3 and G-TAC will promote 14 Pathway tests through G-TAC's personalized medicine platform connected to M3's physician network.
Researchers examined the patient-physician relationship after sharing personal genetic testing results and found that patients may have certain expectations.
Researchers from Brigham and Women's and Harvard surveyed more than 1,600 new customers of 23andMe or Pathway Genomics in the US, of whom 80 were adopted.
The company said it would use the funds to expand its genomic test pipeline, grow its sales force, and invest in new technologies for its laboratories.
The US Department of Justice sued the company for paying doctors to perform its genomic tests, and then obtaining government reimbursements.
The US Food and Drug Administration has sent a letter this week to Pathway Genomics regarding its liquid biopsy cancer screening test.
The agency has sent a letter to the company requesting a meeting to discuss the recently launched liquid biopsy test, saying it may run afoul of FDA rules and regulations.
Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.
The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.
In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.
China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.